Related Experiment Video
Updated: Feb 3, 2026

Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 24, 2010
Clinical Indicators That Identify Risk of Deteriorating and Dying in People with a Hematological Malignancy: A
Elise Button1,2, Nicole C Gavin1, Raymond J Chan3,2
11 Cancer Care Services, Royal Brisbane and Women's Hospital, Queensland University of Technology, Brisbane, Australia.
Background:
Identifying people who are at risk of deteriorating and dying is essential to inform goals of care, appropriate treatment decisions, patient autonomy, and effective end-of-life care. Limited literature exists on predicting survival near the end of life for people with a hematological malignancy.
Objective:
To identify the key clinical indicators that signal a person with a hematological malignancy is at high risk of deteriorating and dying.
Design, Setting, Participants:
Eleven clinical indicators identified in a Delphi approach were tested via a retrospective case-control study. Each indicator was assessed for at each in-patient admission between living (n = 236) and deceased (n = 120) people with a hematological malignancy who were admitted to a large tertiary hospital between 1st July 2014 and 31st December 2015.
Results:
Six clinical indicators were independently associated with mortality in the final three months of life: declining performance status (Odds Ratio [OR] 7.153, 95% Confidence Intervals [CI] 3.281-15.597, p = < 0.001); treatment limitations of the hematological malignancy (OR 7.855, 95% CI 3.528-17.489, p = < 0.001); relapse, refractory or persistent disease (OR 3.749, 95% CI 1.749-8.039, p = 0.001); presence of two or more comorbidities (OR 2.991, 95% CI 1.319-6.781, p = 0.009); invasive fungal infections (OR 4.887, 95% CI 1.197-19.949, p = 0.027); and persistent infections (OR 6.072, 95% CI 2.551-14.457, p = < 0.001).
Conclusions:
This study has identified six clinical indicators that signal a person with a hematological malignancy is at high risk of deteriorating and dying and may benefit from an assessment of palliative needs and proactive planning, along-side appropriate treatment.
Related Concept Videos
Indicators
Kubler Ross's Stages of Dying
In denial, individuals reject the reality of their condition, often thinking, "This isn't true; I feel fine," as a way to protect themselves from...
Mortar Joint Deterioration in Masonry
The...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Relative Risk

